efectos secundarios de la tirzepatide en Tiroides: Riesgos y Precauciones Efectos secundarios de la tirzepatida:

The global incretin-based drugs market was valued at USD 39.4 billion in 2025 and is projected to grow from USD 41.6 billion in 2026 to USD 72.6 billion by 2035, expanding at a CAGR of 6.4% between 2026 and 2035, driven by the rising prevalence of type 2 diabetes mellitus.

Conclusions Dose levels of bimagrumab administered weekly subcutaneously resulted in PK profiles and PD effects comparable with monthly intravenous dosing, which supports the feasibility of the subcutaneous route of administration for bimagrumab for future clinical development.

Semaglutide users often wonder whether fruit fits into their weight loss plan

Overview: Semaglutide is a long-acting GLP-1 receptor agonist analog, developed for glucose regulation, metabolic signaling, and peptide-based receptor studies

A new KFF analysis estimates that 3.8 million Medicare Part D enrollees could qualify for the Medicare GLP-1 Bridge program, which began July 1 and provides temporary coverage of GLP-1s for weight reduction for eligible beneficiaries through December 2027.

This study aimed to establish age- and sex-specific reference percentiles and z-scores for GLP-1, GIP, and glucagon in children and to examine their associations with insulin resistance, lipid status, and metabolic syndrome